Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.70 |
| ▸ | ITGB6 | P18564 | 18/20 | 0.70 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.70 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.70 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.70 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713127 | 1.00 | ITGAV (0.70) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21744205 | 0.94 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21744207 | 0.94 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| Hydrochloric Acid SCHEMBL21713036 | 0.94 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| Hydrochloric Acid SCHEMBL21713035 | 0.94 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21713029 | 0.94 | ITGAV (0.65) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21713033 | 0.94 | ITGAV (0.65) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL21713043 | 0.93 | ITGAV (0.68) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL6879730 | 0.93 | ITGAV (0.68) | ITGAVITGB6ITGB3ITGB1ITGA5 | |
| SCHEMBL5584546 | 0.91 | ITGAV (0.69) | ITGAVITGB6ITGB3ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805284-A | Integrin antagonists | 奥克斯润有限责任公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10703752-B2 | Integrin antagonists | Oxurion NV (BE) | 2020-07-07 | — | — | US | disclosed |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703752-B2 | Integrin antagonists | ITGB1, ITGA2B, ITGA1 | ITGAV 5/4885ITGB6 17/4885ITGB3 11/4885 |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | ITGAV 5/4885ITGB6 17/4885ITGB3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.